Please assess the completion status of the following clinical trial:

Trial Title: Baclofen to Reduce Alcohol Use in Veterans With HCV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Criteria for Participation Include if:~* Male or female~* Age 18 or older~Medical record shows:~* Serum antibody positive for HCV and PCR (Polymerase Chain Reaction) confirmation, Men or Women: \> 7 drinks per week for each of the proceeding 2 weeks Or One heavy drinking day per week for 2 weeks (Heavy drinking day: 5 drinks in one day for men and \>4 drinks in one day for women) based on Timeline Followback method (TLFB)~* Alcohol use Disorder (abuse or dependence) based on Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders (SCID)~  * Yes Medical record and self report~ * Medical record, self report, SCID, Beck Depression Inventory -II (BDI-II)~ * Able to attend clinic appointments~ * Yes No Self-report~Exclusion Criteria:~Criteria for Participation Exclude if:~* Male or female~* Under age 18~* Cocaine, methamphetamine or opioid dependence within the past 6 months\*~* Any known pre-existing medical conditions that could interfere with participation in the protocol, such as:~  * Central Nervous System (CNS) trauma~ * Known cognitive impairment~ * Dementia~ * Encephalopathy from liver disease~ * Acute psychiatric instability, such as significant psychosis, mania, or elevated risk for suicide~* Not able to attend clinic appointments~* Pregnant women~* If any of the following medication are being used:~  * Ondansetron~ * Disulfiram~ * Topiramate~ * Naltrexone~ * Acamprosate~ * Buprenorphine~ * Methadone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Baclofen (Type: EXPERIMENTAL): baclofen 10 mg po tid
- Placebo (Type: PLACEBO_COMPARATOR): placebo given tid

Based on this trial design, predict the completion outcome and termination type (if applicable).